Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Insider & Institutional Ownership
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Amylyx Pharmaceuticals has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Amylyx Pharmaceuticals and Revolution Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 0 | 7 | 1 | 2.89 |
| Revolution Medicines | 1 | 1 | 22 | 1 | 2.92 |
Amylyx Pharmaceuticals presently has a consensus target price of $40.71, suggesting a potential upside of 41.08%. Revolution Medicines has a consensus target price of $242.90, suggesting a potential upside of 26.97%. Given Amylyx Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Amylyx Pharmaceuticals is more favorable than Revolution Medicines.
Profitability
This table compares Amylyx Pharmaceuticals and Revolution Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -52.92% | -48.53% |
| Revolution Medicines | N/A | -88.20% | -57.85% |
Valuation & Earnings
This table compares Amylyx Pharmaceuticals and Revolution Medicines”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $87.37 million | 36.80 | -$144.74 million | ($1.43) | -20.18 |
| Revolution Medicines | N/A | N/A | -$1.13 billion | ($8.82) | -21.69 |
Amylyx Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Amylyx Pharmaceuticals beats Revolution Medicines on 9 of the 12 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
